1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/04/2024 | PFE | Buy Now | Pfizer | $27.71 | 62.4% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
03/01/2024 | PFE | Buy Now | Pfizer | $27.71 | 62.4% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
02/23/2024 | PFE | Buy Now | Pfizer | $27.71 | 29.92% | Guggenheim | Vamil Divan | → $36 | Initiates | → Buy | Get Alert |
01/31/2024 | PFE | Buy Now | Pfizer | $27.71 | 62.4% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
01/09/2024 | PFE | Buy Now | Pfizer | $27.71 | 62.4% | Cantor Fitzgerald | Louise Chen | → $45 | Reiterates | Overweight → Overweight | Get Alert |
01/04/2024 | PFE | Buy Now | Pfizer | $27.71 | 15.48% | TD Cowen | Steve Scala | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
12/14/2023 | PFE | Buy Now | Pfizer | $27.71 | 29.92% | Truist Securities | Robyn Karnauskas | $42 → $36 | Maintains | Buy | Get Alert |
12/14/2023 | PFE | Buy Now | Pfizer | $27.71 | -2.56% | UBS | Colin Bristow | $34 → $27 | Maintains | Neutral | Get Alert |
12/14/2023 | PFE | Buy Now | Pfizer | $27.71 | 1.05% | Barclays | Carter Gould | $34 → $28 | Maintains | Equal-Weight | Get Alert |
12/04/2023 | PFE | Buy Now | Pfizer | $27.71 | 51.57% | Truist Securities | Robyn Karnauskas | → $42 | Reiterates | Buy → Buy | Get Alert |
11/20/2023 | PFE | Buy Now | Pfizer | $27.71 | 170.66% | Cantor Fitzgerald | Louise Chen | → $75 | Reiterates | Overweight → Overweight | Get Alert |
11/01/2023 | PFE | Buy Now | Pfizer | $27.71 | 22.7% | Barclays | Carter Gould | $35 → $34 | Maintains | Equal-Weight | Get Alert |
11/01/2023 | PFE | Buy Now | Pfizer | $27.71 | 33.52% | Morgan Stanley | Terence Flynn | $39 → $37 | Maintains | Equal-Weight | Get Alert |
10/20/2023 | PFE | Buy Now | Pfizer | $27.71 | 22.7% | UBS | Colin Bristow | $36 → $34 | Assumes | Neutral → Neutral | Get Alert |
10/17/2023 | PFE | Buy Now | Pfizer | $27.71 | 51.57% | Truist Securities | Robyn Karnauskas | $62 → $42 | Maintains | Buy | Get Alert |
10/17/2023 | PFE | Buy Now | Pfizer | $27.71 | 40.74% | Morgan Stanley | Terence Flynn | $40 → $39 | Maintains | Equal-Weight | Get Alert |
10/17/2023 | PFE | Buy Now | Pfizer | $27.71 | 26.31% | Wells Fargo | Mohit Bansal | $39 → $35 | Maintains | Equal-Weight | Get Alert |
10/16/2023 | PFE | Buy Now | Pfizer | $27.71 | 19.09% | BMO Capital | Evan David Seigerman | $44 → $33 | Maintains | Outperform | Get Alert |
10/16/2023 | PFE | Buy Now | Pfizer | $27.71 | 26.31% | Citigroup | Andrew Baum | $42 → $35 | Maintains | Neutral | Get Alert |
The latest price target for Pfizer (NYSE: PFE) was reported by Cantor Fitzgerald on March 4, 2024. The analyst firm set a price target for $45.00 expecting PFE to rise to within 12 months (a possible 62.40% upside). 46 analyst firms have reported ratings in the last year.
The latest analyst rating for Pfizer (NYSE: PFE) was provided by Cantor Fitzgerald, and Pfizer reiterated their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on March 4, 2024 so you should expect the next rating to be made available sometime around March 4, 2025.
While ratings are subjective and will change, the latest Pfizer (PFE) rating was a reiterated with a price target of $0.00 to $45.00. The current price Pfizer (PFE) is trading at is $27.71, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.